Breaking News Instant updates and real-time market news.

CNAT

Conatus

$7.58

0.42 (5.87%)

, NVS

Novartis

$73.62

0.88 (1.21%)

08:09
04/21/17
04/21
08:09
04/21/17
08:09

Conatus price target raised to $12 from $4 at Roth Capital

Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.

CNAT

Conatus

$7.58

0.42 (5.87%)

NVS

Novartis

$73.62

0.88 (1.21%)

  • 03

    May

  • 06

    Jun

  • 26

    Jun

CNAT Conatus
$7.58

0.42 (5.87%)

09/20/16
STFL
09/20/16
NO CHANGE
Target $6
STFL
Buy
Stifel says Conatus emricasan an interesting asset amid increased focus on NASH
Following Allergan's (AGN) acquisition of small-cap NASH play Tobira (TBRA), Stifel analyst Stephen Willey notes there are some "interesting" similarities between Conatus (CNAT) and the latter. However, the analyst points out that the clearest distinctions between the two are Conatus' emphasis on some of the downstream consequences of NASH fibrosis and the amount of meaningful clinical data generated to date. Willey still thinks Conatus' emricasan is an interesting asset, but urges investors seeking Tobira-like premiums to exercise a level of caution. He reiterates a Buy rating and $6 price target on Conatus' shares. In afternoon trading, shares of Conatus have gained about 20% to $2.10.
12/20/16
HCWC
12/20/16
NO CHANGE
Target $18
HCWC
Buy
Conatus price target doubled to $18 after Novartis pact at H.C. Wainwright
H.C. Wainwright analyst Ed Arce called Conatus' (CNAT) license and collaboration agreement with Novartis (NVS) a "transformational" deal that he believes ends any uncertainty about whether sufficient financial resources exist to support emricasan's full development. The analyst, who is positive on the deal both strategically and financially and predicted shares Conatus will trade up "at least 100% today," raised his price target on the stock to $18 from $9 and affirmed his Buy rating.
12/20/16
STFL
12/20/16
NO CHANGE
STFL
Conatus price target raised to $7 from $5 at Stifel
Stifel analyst Stephen Willey says that Novartis' (NVS) decision to collaborate with Conatus (CNAT) on its emricasan treatment marks a positive turning point for Conatus. Willey notes that the deal provides Conatus with funding and the opportunity to "pursue combination development with Novartis' FXR agonist LJN452," which he believes has synergies with emricasan. The analyst keeps a Buy rating on Conatus.
12/20/16
RHCO
12/20/16
NO CHANGE
RHCO
Conatus price target raised to $26 from $17 at SunTrust
After Conatus (CNAT) announced a partnership deal with Novartis (NVS), SunTrust analyst John Boris says the deal is "transformational" for Conatus. The analyst thinks that the deal will be worth about $1B to Conatus. He believes that the deal makes strategic sense to Conatus because of the potential synergies in the mechanism of action between its NASH treatment and that of Novartis (NVS). Boris keeps a Buy rating on Conatus.
NVS Novartis
$73.62

0.88 (1.21%)

03/14/17
LEER
03/14/17
NO CHANGE
LEER
Monitoring requests put Novartis Kisqali at marketing disadvantage, says Leerink
Leerink analyst Seamus Fernandez notes that Novartis (NVS) announced the FDA approval of its CDK4/6 inhibitor Kisqali in combination with an aromatase inhibitor for the first-line treatment of post-menopausal women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The analyst says that the label contains warnings for QT prolongation as well as liver toxicity, both of which necessitate frequent monitoring. Although Kisqali appears to have similar efficacy to Pfizer (PFE) approved Ibrance, the latter's label does not include these warnings or monitoring requirements, he points out, adding that he continues to see Ibrance maintaining long-term market dominance in the CDK4/6 class.
04/05/17
COWN
04/05/17
DOWNGRADE
Target $77
COWN
Market Perform
Novartis downgraded to Market Perform from Outperform at Cowen
Cowen analyst Steve Scala downgraded Novartis to Market Perform and lowered his price target for the shares to $77 from $87. The analyst believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout.
04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

AAPL

Apple

$142.27

-0.17 (-0.12%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

13:57
04/22/17
04/22
13:57
04/22/17
13:57
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$142.27

-0.17 (-0.12%)

FB

Facebook

$143.68

-0.12 (-0.08%)

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

AKS

AK Steel

$6.72

-0.1 (-1.47%)

X

U.S. Steel

$30.42

-0.09 (-0.29%)

NUE

Nucor

$60.00

-0.35 (-0.58%)

CYH

Community Health

$8.24

-0.11 (-1.32%)

HCA

HCA Holdings

$83.55

-0.57 (-0.68%)

LPNT

LifePoint

$60.85

-0.7 (-1.14%)

THC

Tenet

$15.35

0.36 (2.40%)

UHS

Universal Health

$118.84

-0.29 (-0.24%)

HUM

Humana

$213.67

-0.57 (-0.27%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

USB

U.S. Bancorp

$50.51

-0.17 (-0.34%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 25

    May

  • 06

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JNS

Janus Capital

$13.15

-0.07 (-0.53%)

13:27
04/22/17
04/22
13:27
04/22/17
13:27
Conference/Events
Janus Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ABT

Abbott

$43.53

-0.45 (-1.02%)

, ABBV

AbbVie

$63.82

0.04 (0.06%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
National Kidney Foundation to hold clinical meeting »

NKF 2017 Spring Clinical…

ABT

Abbott

$43.53

-0.45 (-1.02%)

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

GSK

GlaxoSmithKline

$40.78

0.07 (0.17%)

HZNP

Horizon Pharma

$14.99

-0.25 (-1.64%)

MNK

Mallinckrodt

$43.52

-1.41 (-3.14%)

MRK

Merck

$61.89

-0.66 (-1.06%)

AUPH

Aurinia Pharmaceuticals

$7.11

0.11 (1.57%)

NXTM

NxStage Medical

$27.90

-0.19 (-0.68%)

PLX

Protalix

$1.02

0.02 (2.00%)

RTRX

Retrophin

$18.47

-0.37 (-1.96%)

SNY

Sanofi

$44.09

-0.7 (-1.56%)

SHPG

Shire

$171.94

0.08 (0.05%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

  • 23

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

RGEN

Repligen

$35.06

-0.78 (-2.18%)

19:19
04/21/17
04/21
19:19
04/21/17
19:19
Initiation
Repligen initiated at First Analysis »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 30

    May

  • 06

    Jun

TWTR

Twitter

$14.63

-0.02 (-0.14%)

18:07
04/21/17
04/21
18:07
04/21/17
18:07
Periodicals
Homeland Security investigates potential abuse in Twitter case, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

17:46
04/21/17
04/21
17:46
04/21/17
17:46
Periodicals
Waymo:Uber misled court on Levandowski using LIDAR secrets, Bloomberg says »

According to Bloomberg,…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
CareDx receives expected letter from Nasdaq »

CareDx announced that, as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$44.45

-0.2 (-0.45%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
Greenbrier CEO intends to sell one-half of his position in company stock »

The CEO of The Greenbrier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx backs FY17 revenue view $45M-$50M, consensus $47.62M »

Revenue view excludes any…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx reports Q4 adjusted EPS (13c), consensus (18c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$1.69

-0.05 (-2.87%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Hot Stocks
Alliance MMA announces shareholder filed lawsuit against the company »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:30
04/21/17
04/21
17:30
04/21/17
17:30
Hot Stocks
CareDx names Michael Bell CFO »

CareDx announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

, XOMA

XOMA

$7.73

0.26 (3.48%)

17:22
04/21/17
04/21
17:22
04/21/17
17:22
Hot Stocks
Novo Nordisk terminates exclusive license agreement with XOMA »

On April 20, XOMA (XOMA)…

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

XOMA

XOMA

$7.73

0.26 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 18

    May

  • 06

    Jun

HH

Hooper Holmes

$0.72

-0.1973 (-21.44%)

17:21
04/21/17
04/21
17:21
04/21/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Hooper Holmes »

John Pappajohn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$28.00

0.15 (0.54%)

17:14
04/21/17
04/21
17:14
04/21/17
17:14
Earnings
First Bancshares reports Q1 EPS 12 c with items, consensus 35c »

Reports Q1 provision for …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRWI

DragonWave

$1.23

-0.025 (-2.00%)

17:04
04/21/17
04/21
17:04
04/21/17
17:04
Hot Stocks
DragonWave did not regain compliance with Nasdaq listing standards »

DragonWave announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:02
04/21/17
04/21
17:02
04/21/17
17:02
Hot Stocks
Sears establishes special committee to market certain real estate properties »

Sears Holdings said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
Sears names Rob Riecker CFO »

Sears announced that Rob…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

UAL

United Continental

$69.56

-0.24 (-0.34%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
UAL: employee incentive opportunity to be tied to 'customer experience' »

United Continental said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Earnings
Sears sees FY17 net income $185M-$285M »

"The retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

16:59
04/21/17
04/21
16:59
04/21/17
16:59
Hot Stocks
Sears raises annualized cost savings target to $1.25B from $1B »

Sears Holdings provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

LTBR

Lightbridge

$1.25

-0.06 (-4.58%)

16:51
04/21/17
04/21
16:51
04/21/17
16:51
Hot Stocks
CEO of Lightbridge Seth Grae reports 5.1% stake in company »

As of March 22, Seth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

16:46
04/21/17
04/21
16:46
04/21/17
16:46
Syndicate
Breaking Syndicate news story on Ionis Pharmaceuticals »

Ionis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.